Pylaify f-18 injection radiopharmaceuticals
Ended Awarded Last action
- Contract number
- 36C24526N0276
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $599,048
Award facts
- Opportunity
-
- 36C24526Q0215 Solicitation number
- Contract value 100% obligated
- $599,047.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Bedford, MA 01730, USA
Award details come from SAM.gov/FPDS.
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a $599,047.52 firm fixed-price delivery order by Veterans Integrated Service Network 5 on February 1, 2026, for PYLARIFY (piflufolastat F-18) injection radiopharmaceuticals. The contract, with an ultimate completion date of March 1, 2026, contains no set-aside designation and represents performance at the company's facility in Bedford, Massachusetts. This delivery order falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a master contract vehicle that enables the Veterans Health Administration to efficiently procure critical radiopharmaceutical products. PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography scans for the detection and localization of prostate cancer, providing essential diagnostic capabilities for veterans and military personnel served through the VA healthcare system.
Progenics Pharmaceuticals maintains an extensive federal contracting portfolio with the Department of Veterans Affairs across multiple Veterans Integrated Service Networks, the Defense Health Agency, and the National Institutes of Health Clinical Center. The company holds a substantial $290 million Federal Supply Schedule contract with Veterans Integrated Service Network 12 extending through March 31, 2030, along with multiple blanket purchase agreements and indefinite delivery vehicles with various VISNs and federal agencies. This delivery order reflects the company's established role as a primary supplier of specialized radiopharmaceutical products supporting federal healthcare providers' oncology diagnostic imaging programs, with a consistent track record of over 150 individual federal contract awards ranging in value from approximately $10,000 to over $9 million.
Quick answers
Who was awarded contract 36C24526N0276?
36C24526N0276 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on February 1, 2026.
How much is contract 36C24526N0276 worth?
The government has obligated $599,048 on 36C24526N0276.
Is contract 36C24526N0276 an order under another contract?
Yes. 36C24526N0276 is a delivery order under 36F79725D0093, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0276 competed?
The extent of competition for 36C24526N0276 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award